Fulgent (FLGT) - Long-Term Liabilities to Capital

Fulgent Genetics, Inc. (FLGT) maintains an impeccable reputation among physicians due to its precise bioinformatic analysis and rapid delivery of test results. This daily price chart illustrates the synergy between the IT approach and medicine created by the expert team, while long-term debt equals 0.01. The company's operations are further complemented by a responsible approach to plastic recycling and the optimization of transport routes to reduce harmful emissions.

The long-term debt-to-equity ratio distinguishes sustainable business models from speculative ones by measuring the proportion of borrowed funds with a maturity of over one year within the financing structure. An analysis of long-term debt relative to equity confirms the financial strength of Fulgent Genetics, Inc. (FLGT), whose excess cash reserves neutralize credit risks and ensure the autonomous development of its oncology segment without external debt burdens.